je.st
news
Tag: merck
Merck Receives Positive CHMP Opinion for ZEPATIER (elbasvir and grazoprevir) in the European Union
2016-05-27 13:46:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of ZEPATIER (elbasvir and grazoprevir), an investigational, once-daily, fixed-dose combination tablet for the treatment of chronic hepatitis C virus (HCV) in adult patients. The CHMP positive opinion will be reviewed by the European Commission. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orSarra Herzog, 908-740-1871orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: the
positive
opinion
union
Merck Announces Third-Quarter 2016 Dividend
2016-05-24 20:35:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.46 per share of the companys common stock for the third quarter of 2016. Payment will be made on July 8, 2016 to shareholders of record at the close of business on June 15, 2016. About Merck Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036orInvestors:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: announces
dividend
merck
announces thirdquarter
Merck to Present at the UBS Global Healthcare Conference
2016-05-24 14:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Adam Schechter, executive vice president and president, Global Human Health, Merck, is scheduled to present at the UBS Global Healthcare Conference in New York on May 25, 2016 at 8:00 a.m. EDT. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at http://investors.merck.com/investors/webcasts-and-presentations/default.aspx. Language: English Contact: Media:Lainie Keller, (908) 236-5036orInvestor:Teri Loxam, (908) 740-1986Justin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: present
global
conference
healthcare
Merck Announces FDA Accepts Samsung Bioepis Biologics License Application (BLA) for SB2 (Infliximab), an Investigational Biosimilar of Remicade
2016-05-24 01:50:08| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. First BLA Filed by Samsung Bioepis as Part of Its Partnership with Merck KENILWORTH, N.J. Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) submitted by Samsung Bioepis Co., Ltd. for SB2 (infliximab), an investigational biosimilar candidate of Remicade. Language: English read more
Tags: of
application
license
samsung
Merck Foundation Announces the Alliance to Advance Patient-Centered Cancer Care, a $15 Million Initiative to Improve Access to High-Quality Cancer Care in Underserved Communities in the United States
2016-05-23 15:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Merck Foundation Accepting Applications from Non-Profit Organizations KENILWORTH, N.J.--(BUSINESS WIRE)--The Merck Foundation announced today the launch of a new initiative, the Alliance to Advance Patient-Centered Cancer Care (the Alliance), to support programs aimed at improving timely access to patient-centered care and reduce disparities in cancer care, especially for vulnerable and underserved populations in the United States. Language: English Contact: Media:Lainie Keller, 908-236-5036orCourtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Sites : [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] next »